Navigation Links
Promising cell protein may play role in infection and dry eye

Plasminogen Activator Inhibitor Type 2 (PAI-2), a protein found in various cell types including the skin, has been discovered in the tissue covering the eye and may have future clinical implications in various pathologies of the ocular surface such as eye infection or dry eye, according to researchers at the University of Pennsylvania and Temple University.

The researchers, led by Mina Massaro-Giordano, M.D., of the University of Pennsylvania's Scheie Eye Institute, and Marcella Macaluso, Ph.D., of the Sbarro Institute for Cancer Research at Temple University (www.shro.org), published their study,

"Cytoplasmic and nuclear interaction between Rb family proteins and PAI-2: a physiological crosstalk in human corneal and conjunctival epithelial cells," in Cell Death and Differentiation (www.nature.com/cdd).

They recently presented their findings at the annual meeting of the Association of Research in Vision and Ophthalmology (ARVO) in Florida, which was attended by over 10,000 researchers.

PAI-2, in either extracellular or secreted form, is a multifunctional protein that plays a role in cell differentiation, in prevention of programmed cell death, in the regulation of cell proliferation, in the inhibition of microbial proteinases and in the protection against stromal degradation.

High levels of the PAI-2 protein are associated with a good prognosis in breast cancer, small cell lung, ovarian cancer, and inhibition of metastasis. PAI-2 also plays a role in inflammation on the surface of the eye.

In their study, the Penn and Temple researchers demonstrate for the first time an interaction between PAI-2 and the tumor suppressing gene Rb2/p130 in the nucleus of the epithelial cells in the cornea and conjunctiva.

According to the researchers, this interaction with Rb2/p130 and chromatin modeling enzymes may affect how PAI-2 is expressed.


'"/>

Source:Temple University


Page: 1 2

Related biology news :

1. Another Look Finds Promising Proteomics Test is Not Biologically Plausible
2. Promising new West Nile therapy cures disease in mice
3. Promising therapies for haemophilia & heart disease
4. New, automated tool successfully classifies and relates proteins in unprecedented way
5. New binding target for oncogenic viral protein
6. Controversial drug shown to act on brain protein to cut alcohol use
7. Timing is everything: First step in protein building revealed
8. UWs Rosetta software to unlock secrets of many human proteins
9. Researchers find how protein allows insects to detect and respond to pheromones
10. Signaling protein builds bigger, better bones in mice
11. Ancient olfaction protein is shared by many bugs, offering new pest control target
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Promising cell protein may play role infection and dry eye

(Date:2/5/2015)... -- New Market Research Reports Title Global ... 2020 has Been Added to GrandViewReseach.com Report Database ... reach USD 5.10 billion by 2020, according to a ... help identify the site of tissue damage in case ... in medical imaging applications. They have been extensively used ...
(Date:2/5/2015)... DUBLIN , Jan. 28, 2015 Research ... announced the addition of the "Global Biometrics ... Use, Regions and Countries " report to their ... market, Asia-Pacific is anticipated ... by 2015, owing to increasing government spending towards ...
(Date:2/5/2015)... Feb. 3, 2015 Despite a lack ... industries such as consumer electronics, automotive, storage and ... mount technology (SMT) screen printers. Innovations in electronics ... will push the adoption curve up. Meanwhile, sale ... as glue dispensers are indispensable in the production ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3
... the mechanical strength of cancer cell mucus layers provides ... suggests why some cancer cells are more resistant to ... of engineering at Northeastern University, Boston, Mass. ... protect against infection. Cancer cells, however, produce far more ...
... March, 2011 A recent special edition of the journal ... of the British Mycological Society, features a total of 76 ... cell biology movies ever published. The movies were produced by ... is a renowned researcher in the field of fungal cell ...
... A Purdue University scientist,s nanopolymer would make it easier ... of a widely used class of cancer inhibitors. ... chemistry and a member of the Purdue Center for ... can be used to determine whether cancer drugs have ...
Cached Biology News:Breaking the mucus barrier unveils cancer cell secrets 2Purdue startup hopes to change the way we test cancer drugs 2
(Date:2/26/2015)... NEW YORK , Feb. 26, 2015 ... commenced Factual Stock Report coverage on MabVax Therapeutics ... Inc. (MBVX) is a clinical stage biotechnology company focused ... address unmet medical needs in the treatment of cancer. ... products based on the protective immune responses generated by ...
(Date:2/26/2015)... Feb. 26, 2015   Regulus Therapeutics Inc . ... the discovery and development of innovative medicines targeting microRNAs, ... President and Chief Executive Officer of Regulus, will present ... th Annual Healthcare Conference on Wednesday, March 4, ... held at the Boston Marriott Copley Place.  ...
(Date:2/26/2015)...  NuGene International, Inc. ("NuGene") (OTCQB: NUGN), the ... hair rejuvenation, has announced that it has selected ... investor relations and strategic communications. ... diversification strategies – and we need to communicate ... Ali Kharazmi CEO of NuGene when announcing this ...
(Date:2/26/2015)... Innovation is more urgent than ever. Radical ... the world and transforming global markets in industry ... health care, disruption is constantly underway. , As ... shake the foundations of established business models, large-scale ... survive the next wave of mega-change. , This ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3One Million Acts of Innovation Canada Creates Partnership with The Economist Events’ Innovation Forum 2
... ... and Ralph M. Lerner named Senior Vice President of Commercial Development , ... Marlborough, Mass. (Vocus) October 23, ... technology turns biomass into cellulosic ethanol, has welcomed Kevin F. McLaughlin and Ralph M. ...
... Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ... overview of the Company at the 8th Annual BIO ... 3:00 p.m. PT. The conference will be held at ... and 29, 2009. , A live audio link to ...
... Oct. 23 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... global biopharmaceutical company focused on endocrine therapy and ... previously announced registered direct offering of US$5.5 million ... share purchase warrants to certain institutional investors. AEterna ...
Cached Biology Technology:Cellulosic Biofuels Leader Qteros Adds Key Positions 2Cellulosic Biofuels Leader Qteros Adds Key Positions 3Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2009 2AEterna Zentaris Receives US$5.5 Million from Institutional Investors 2AEterna Zentaris Receives US$5.5 Million from Institutional Investors 3
Takara's Mutan-Super Express Km Kit is designed to achieve site-directed mutagenesis in just one day. It is based on Oligonucleotide-directed Dual Amber (ODA) method, using the advantages of LA (Long...
...
...
Newborn Calf Serum US Origin...
Biology Products: